Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers
Journal of Personalized Medicine · 16.04.2026 · 16 (4) · 220
DOI: 10.3390/jpm16040220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 16.04.2026. Verfasst von Konstantinos Kapriniotis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Whipps Cross University Hospital, London E11 1NR, UK. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Upper tract urothelial carcinoma is a rare disease with variable prognosis depending on the stage and grade at diagnosis. Current modalities are far from perfect in diagnosis and risk stratification. In this setting, there is an urgent need for diagnostic and prognostic biomarkers to overcome these limitations.
Methods
We carried out a narrative review of the literature searching for research articles on diagnostic and prognostic biomarkers for upper tract urothelial carcinoma (UC) and underlined the limitations of current diagnostic modalities.
Results
CT urogram (CTU) is the imaging modality of choice in suspected upper tract UC with sensitivity and specificity exceeding 90% but with limitations in smaller lesions. Urine cytology has an excellent specificity for high-grade UC but is limited by low sensitivity leading to a high number of diagnostic ureteroscopies with significant associated risks. Adjuncts such as Fluorescence In Situ Hybridization (FISH) technology and urine DNA methylation markers have shown promising results but need further validation in large cohorts of upper tract UC. Finally, circulation tumour DNA (ctDNA) is a novel approach with great potential in risk stratification and monitoring of minimal residual disease post radical surgery; however, larger prospective studies are required to validate its role similarly to the recent bladder UC trials.
Conclusions
There is an urgent need for non-invasive biomarkers that can reliably replace diagnostic ureteroscopies, identify high-risk/invasive disease and select patients for radical surgery or kidney sparing procedures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Whipps Cross University Hospital, London E11 1NR, UK.
- Department of Urology, Royal Free Hospital, London NW3 2QG, UK.
- Department of Urology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
- 2nd Department of Urology, National and Kapodistrian University of Athens, 151 26 Athens, Greece.
ORCID-Profile: Mohammad U Sharif, Ioannis Manolitsis, Lazaros Tzelves
Zitieren
APA
Kapriniotis, K., Loufopoulos, I., Sharif, M. U., Manolitsis, I., Tzelves, L., Nagle, A., & Green, J. S. A. (2026). Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers. Journal of Personalized Medicine, 16(4), 220. https://doi.org/10.3390/jpm16040220
Vancouver
Kapriniotis K, Loufopoulos I, Sharif MU, Manolitsis I, Tzelves L, Nagle A, et al. Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers. Journal of Personalized Medicine. 2026;16(4):220. doi:10.3390/jpm16040220
BibTeX
@article{Kapriniotis2026,
author = {Kapriniotis, Konstantinos and Loufopoulos, Ioannis and Sharif, Mohammad U and Manolitsis, Ioannis and Tzelves, Lazaros and Nagle, Amy and Green, James S A},
title = {Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {4},
pages = {220},
doi = {10.3390/jpm16040220}
}
EUVIMED